AFP和HCCR-1联合检测在诊断小肝癌中的作用

Effects of combined detection of AFP and HCCR-1 in diagnosis of small hepatocellular carcinoma

目的:探讨AFP和HCCR-1联合检测在诊断小肝癌中的作用。方法:检测肝癌患者体内AFP和HCCR-1表达水平。结果:1 258例肝癌患者血清中AFP和HCCR-1的检测结果:AFP检测阳性率是576(46%),HCCR-1检测的阳性率是646(51.3%)。当AFP和HCCR-1联合检测时阳性率提高到74.1%。AFP和HCCR-1分别检测小肝癌(直径小于2厘米)的阳性率是40.1%和23.4%,二者联合检测时阳性率上升为56.9%。结论:实验结果表明HCCR-1可以作为检测肝癌的有用标志物,当AFP和HCCR-1结合在一起检测,能提高小肝癌的阳性率。

Objective： To discuss effects of combined detection of AFP and HCCR-1 in diagnosis of small hepatocellular carcinoma. Methods： The levels of AFP and HCCR- 1 in the patients with liver cancer were detected. Results： Of the 1258 cases of liver cancer patients,576（ 46%） and 646（ 51. 3%） cases were positive for AFP and HCCR- 1,respectively. In the combined detection of AFP and HCCR- 1,the positive rate for liver cancer increased up to 74. 1%. The positive rate for small hepatocellular carcinoma（ diameter 〈2 cm） increased to 56.9% in the combined detection of AFP and HCCR-1,although those were only 40.1% and 23.4% of AFP ad HCCR- 1,respectively. Conclusions： It suggests that the HCCR- 1 is a useful biomarker for liver cancer. The positive rate of small hepatocellular carcinoma could be significantly improved in the combined detection of HCCR- 1 and AFP.